These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 9675550

  • 1. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
    Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA.
    Drugs Exp Clin Res; 1998; 24(2):93-104. PubMed ID: 9675550
    [Abstract] [Full Text] [Related]

  • 2. In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line.
    Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA.
    Anticancer Drugs; 1996 Jun; 7(4):469-75. PubMed ID: 8826615
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
    Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakóbisiak M, Golab J.
    Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
    [Abstract] [Full Text] [Related]

  • 8. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
    Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y.
    Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
    [Abstract] [Full Text] [Related]

  • 9. Antiproliferative activity of vitamin D compounds in combination with cytostatics.
    Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A, Opolski A.
    Anticancer Res; 2006 Sep; 26(4A):2701-5. PubMed ID: 16886680
    [Abstract] [Full Text] [Related]

  • 10. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 11. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y, Akutsu M, Tsunoda S, Furuta M, Yazawa Y, Ando J.
    Oncol Res; 1998 Sep; 10(7):347-54. PubMed ID: 10063968
    [Abstract] [Full Text] [Related]

  • 12. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP, Urben CM, Strugnell SA, Knutson JC.
    Anticancer Res; 2004 Sep; 24(5A):2905-12. PubMed ID: 15517895
    [Abstract] [Full Text] [Related]

  • 13. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK, Agarwal C, Chan DC, Agarwal R.
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [Abstract] [Full Text] [Related]

  • 14. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R, Tanabe K, Inoue H, Toge T.
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [Abstract] [Full Text] [Related]

  • 15. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A.
    Anticancer Res; 2004 Mar; 24(2B):865-71. PubMed ID: 15161039
    [Abstract] [Full Text] [Related]

  • 16. Effects of the Medicago scutellata trypsin inhibitor (MsTI) on cisplatin-induced cytotoxicity in human breast and cervical cancer cells.
    Lanza A, Tava A, Catalano M, Ragona L, Singuaroli I, Robustelli della Cuna FS, Robustelli della Cuna G.
    Anticancer Res; 2004 Mar; 24(1):227-33. PubMed ID: 15015601
    [Abstract] [Full Text] [Related]

  • 17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ.
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [Abstract] [Full Text] [Related]

  • 19. [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549].
    Zhang X, Li Q, Han Y, Liu Z.
    Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):537-9. PubMed ID: 12667319
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y.
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.